Mylan garners FDA approval for generic version of Astellas' Prograf

Mylan reported that it garnered final FDA approval to market generic versions of Astellas' Prograf (tacrolimus) capsules, in various dosages, as a treatment to prevent rejection in people who have received certain organ transplants. Mylan said that it plans to begin sales of the drug immediately.

Prograf capsules had US sales of approximately $944 million for the 12 months ending June 30, according to IMS Health. In July, Watson Pharmaceuticals also received FDA approval to sell a generic version of the drug.

> As medicine reaches the mobile, the question is which are the best apps, who’s using them, and how?
Trends in Mobile Medicine: Smartphone Apps for Physicians - click here to find out more

To read more Top Story articles, click here.